uniQure

194 articles about uniQure

• 

  Is the Push for Lower Drug Prices Surging Again?

  4/26/2018

  During the 2016 U.S. presidential election, the push for lower drug prices became one of the hot-button topics. Now there appears to be some efforts by advocacy groups and government entities to tackle the subject in several different ways.

• uniQure Announces Updated, Long-Term Clinical Data From Ongoing Phase I/II Trial of AMT-060 in Patients With Severe Hemophilia B

  12/11/2017

  The data includes up to two years of follow-up from the low-dose cohort and up to 18 months of follow-up from the second, higher-dose cohort.

• 

  uniQure Researchers Swap Out Lead Drug for a Better Prospect

  10/19/2017

  The company plans to expeditiously advance AMT-061 instead of AMT-060.

• uniQure: A Busted Biotech IPO Worth Owning

  8/22/2017

• uniQure Announces The Successful Development And Scale-Up Of Manufacturing Processes For Its Hemophilia B Gene Therapy Program

  7/21/2017

• uniQure Expands Intellectual Property Portfolio With Newly Issued Patent Providing Broad Protection Of Insect Cell-Based AAV Manufacturing

  7/18/2017

• uniQure Presents New Clinical Data In Hemophilia B Patients Demonstrating Therapeutic Efficacy Of AAV5 Gene Therapy In The Presence Of Pre-Existing Neutralizing Antibodies

  7/11/2017

• uniQure Announces Clinical Data Presentations At The Upcoming International Society On Thrombosis And Hemostasis (ISTH) Congress

  6/23/2017

• uniQure Publishes Data Further Demonstrating Favorable Immunogenicity Profile And Broad Utilization Of AAV5-Based Gene Therapies

  6/15/2017

• uniQure Presents New Data Demonstrating Successful And Effective Transduction Of AAV5 Vector In The Presence Of Pre-Existing Neutralizing Antibodies In Non-Human Primates

  5/10/2017

• uniQure Announces First Quarter 2017 Financial Results And Highlights Recent Company Progress

  5/9/2017

• uniQure Presents New Preclinical Data On AMT-130 In Huntington’s Disease At CHDI’s 12th Annual Huntington’s Disease Therapeutics Conference

  4/26/2017

• uniQure Receives EMA Priority Medicines (PRIME) Designation For AMT-060 In Hemophilia B

  4/25/2017

• uniQure Announces It Will Not Seek Marketing Authorization Renewal For Glybera In Europe

  4/20/2017

• uniQure Publishes Data Demonstrating Wide Distribution Of AAV5 In The Central Nervous System

  4/4/2017

• uniQure Announces Presentations At Upcoming April Conferences

  4/3/2017

• uniQure Announces 2016 Financial Results And Provides Update On Company Progress

  3/15/2017

• uniQure Receives 2017 Frost & Sullivan Manufacturing Leadership Award

  3/3/2017

• uniQure Announces Presentations At Upcoming March Conferences

  3/1/2017

• uniQure Announces Presentations At Upcoming February Conferences

  2/6/2017